J B Hunt Transport Services Inc vs Twist Bioscience Corp — how do they compare? J B Hunt Transport Services Inc trades at $290.57 (market cap $27.36B), while Twist Bioscience Corp trades at $88.43 (market cap $5.45B). The key difference: J B Hunt Transport Services Inc is far larger — about 5× Twist Bioscience Corp's market cap, and J B Hunt Transport Services Inc pays a 0.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| JBHT | TWST | |
|---|---|---|
Market Cap | $27.36B | $5.45B |
Sector | Industrials | Health |
52-Week High | $298.41 | $102.88 |
52-Week Low | $130.65 | $24.16 |
Enterprise Value | $28.50B | $5.37B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Trailing returns across standard periods
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →